Index,A_P,A_I,A_C,A_O,A_S,A_Decision,A_Reason
0,patients with advanced biliary tract cancer,pembrolizumab plus gemcitabine and cisplatin,placebo plus gemcitabine and cisplatin,overall survival,"randomised, double-blind, placebo-controlled, phase 3 trial",False,"population mismatch (biliary tract cancer, not hepatocellular carcinoma)"
1,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,overall survival,"open-label, phase 3, multicentre, non-inferiority trial",False,"intervention mismatch (lenvatinib, not immune checkpoint inhibitors)"
2,patients with unresectable hepatocellular carcinoma,atezolizumab plus bevacizumab,sorafenib,overall survival and progression-free survival,"global, open-label, phase 3 trial",False,study design mismatch (not CheckMate RCT)
3,patients with unresectable hepatocellular carcinoma,atezolizumab plus bevacizumab,sorafenib,overall survival and progression-free survival,"open-label, phase III study",False,study design mismatch (not CheckMate RCT)
4,patients with unresectable hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,progression-free survival and overall survival,"randomised, open-label, international phase 3 trial",False,study design mismatch (not CheckMate RCT)
5,patients with unresectable hepatocellular carcinoma,tremelimumab plus durvalumab,sorafenib,overall survival,"global, open-label, phase 3 trial",False,study design mismatch (not CheckMate RCT)
6,patients with unresectable hepatocellular carcinoma,tremelimumab plus durvalumab,sorafenib,overall survival,"global, open-label, phase 3 trial",False,study design mismatch (not CheckMate RCT)
7,"patients with HER2-negative, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer",nivolumab plus oxaliplatin-based chemotherapy,placebo plus oxaliplatin-based chemotherapy,progression-free survival and overall survival,"randomised, multicentre, double-blind, placebo-controlled, phase 2-3 trial",False,"population mismatch (gastric or gastro-oesophageal junction cancer, not hepatocellular carcinoma)"
8,patients with advanced hepatocellular carcinoma,lenvatinib plus transarterial chemoembolization,lenvatinib monotherapy,overall survival,"multicenter, randomized, open-label, parallel group, phase III trial",False,"intervention mismatch (lenvatinib, not immune checkpoint inhibitors)"
9,patients with unresectable hepatocellular carcinoma,lenvatinib plus pembrolizumab,lenvatinib plus placebo,overall survival and progression-free survival,"global, randomised, double-blind, phase 3 study",False,study design mismatch (not CheckMate RCT)
10,patients with advanced hepatocellular carcinoma previously treated with sorafenib,cabozantinib,placebo,"overall survival, progression-free survival, objective response rate","randomized, double-blind, phase 3 trial",False,intervention is not an immune checkpoint inhibitor
11,"patients with advanced hepatocellular carcinoma, no previous systemic therapy",nivolumab,sorafenib,overall survival,"randomized, open-label, phase 3 trial",True,matches PICOS criteria: nivolumab is an immune checkpoint inhibitor
12,patients with hepatocellular carcinoma who progressed on sorafenib,regorafenib,placebo,overall survival,"randomized, double-blind, phase 3 trial",False,intervention is not an immune checkpoint inhibitor
13,patients with unresectable HBV-associated hepatocellular carcinoma,sintilimab plus IBI305,sorafenib,"overall survival, progression-free survival","randomized, open-label, phase 2-3 trial",True,matches PICOS criteria: sintilimab is an immune checkpoint inhibitor
14,patients with advanced hepatocellular carcinoma previously treated with sorafenib,nivolumab plus ipilimumab,not specified,"objective response rate, duration of response","multicenter, open-label, phase 1/2 study",True,matches PICOS criteria: nivolumab and ipilimumab are immune checkpoint inhibitors
15,"patients with unresectable hepatocellular carcinoma, no previous systemic therapy",tislelizumab,sorafenib,"overall survival, objective response rate, progression-free survival","open-label, global, phase 3 trial",True,matches PICOS criteria: tislelizumab is an immune checkpoint inhibitor
16,hepatocellular carcinoma patients with microvascular invasion,FOLFOX-HAIC,routine follow-up,"disease-free survival, overall survival","randomized, open-label, multicenter trial",False,intervention is not an immune checkpoint inhibitor
17,patients with unresectable hepatocellular carcinoma,FOLFOX-HAIC,TACE,"overall survival, progression-free survival","randomized, multicenter, open-label trial",False,intervention is not an immune checkpoint inhibitor
18,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,"overall survival, progression-free survival, objective response rate","randomized, non-inferiority, phase 3 trial",False,intervention is not an immune checkpoint inhibitor
19,patients with hepatocellular carcinoma beyond Milan criteria,liver transplantation,non-transplantation therapies,"tumor event-free survival, overall survival","open-label, randomized, controlled trial",False,intervention is not an immune checkpoint inhibitor
20,patients with advanced hepatocellular carcinoma,atezolizumab + bevacizumab,tyrosine kinase inhibitors or other therapies,recommended care options,systematic review of phase III RCTs,False,"outcome is not survival or response rate, study design not CheckMate RCT"
21,patients with unresectable HCC,atezolizumab plus bevacizumab,lenvatinib,overall survival,retrospective multi-centre study,False,"study design is not RCT, not CheckMate RCT"
22,patients with advanced hepatocellular carcinoma,cabozantinib plus atezolizumab,sorafenib or single-agent cabozantinib,"progression-free survival, overall survival","open-label, randomised, phase 3 trial",False,study design not CheckMate RCT
23,patients with hepatocellular carcinoma and portal vein invasion,sorafenib plus HAIC,sorafenib alone,"overall survival, response rate","randomized, open-label clinical trial",False,study design not CheckMate RCT
24,patients with advanced HCC and high α-fetoprotein,ramucirumab,placebo,"overall survival, progression-free survival","randomised, double-blind, phase 3 trial",False,study design not CheckMate RCT
25,patients with advanced intrahepatic cholangiocarcinoma,"toripalimab, lenvatinib, and GEMOX",not specified,"objective response rate, overall survival","phase-III, multicenter, double-blinded, randomized study",False,"population not hepatocellular carcinoma, study design not CheckMate RCT"
26,patients with advanced HCC,donafenib,sorafenib,"overall survival, progression-free survival","open-label, randomized, phase II-III trial",False,study design not CheckMate RCT
27,patients with advanced HCC previously treated with sorafenib,pembrolizumab,placebo,"overall survival, progression-free survival","randomized, double-blind, phase III study",False,study design not CheckMate RCT
28,patients with intermediate-stage HCC,lenvatinib plus pembrolizumab plus TACE,placebos plus TACE,"overall survival, progression-free survival","prospective, double-blind randomized phase 3 study",False,study design not CheckMate RCT
29,patients with unresectable HCC,TACE plus sorafenib,TACE alone,"progression-free survival, overall survival",randomized trial,False,study design not CheckMate RCT
30,patients with unresectable hepatocellular carcinoma,tremelimumab and durvalumab as monotherapies and in combination,different dosing regimens of tremelimumab and durvalumab,overall survival and objective response rate,phase I/II study,False,study design is not CheckMate RCT
31,patients from Asia with previously treated advanced hepatocellular carcinoma,pembrolizumab,placebo,"overall survival, progression-free survival, and objective response rate","double-blind, phase III trial",False,study design is not CheckMate RCT
32,patients with intermediate-stage hepatocellular carcinoma,yttrium 90 transarterial radioembolization,doxorubicin drug-eluting bead transarterial chemoembolization,time to overall tumor progression and overall survival,single-center prospective randomized controlled trial,False,study design is not CheckMate RCT
33,patients with hepatocellular carcinoma,anti-PD-1 immunotherapy,not specified,early detection and efficacy assessment of immunotherapy,not specified,False,study design and comparison not specified
34,patients with advanced hepatocellular carcinoma and major portal vein tumor thrombosis,sorafenib plus hepatic arterial infusion chemotherapy,sorafenib alone,"overall survival, objective response rate, and progression-free survival",phase II trial,False,study design is not CheckMate RCT
35,patients with unresectable hepatocellular carcinoma,lenvatinib vs. sorafenib,not specified,overall survival and objective response,phase III study,False,study design is not CheckMate RCT
36,patients with hepatocellular carcinoma after surgical resection or local ablation,sorafenib,placebo,recurrence-free survival,"phase 3, double-blind, placebo-controlled study",False,study design is not CheckMate RCT
37,patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization,Fuzheng Jiedu Xiaoji formulation combined with standard treatment,standard treatment alone,overall survival and progression-free survival,randomized controlled clinical trial,False,study design is not CheckMate RCT
38,patients with hepatocellular carcinoma of BCLC stages A or B,yttrium-90 radioembolization,conventional transarterial chemoembolization,time to progression and survival time,"randomized, phase 2 study",False,study design is not CheckMate RCT
39,patients with pretreated advanced hepatocellular carcinoma,apatinib,placebo,overall survival,"randomised, double-blind, placebo-controlled, phase 3 trial",False,study design is not CheckMate RCT
40,patients with advanced hepatocellular carcinoma,HAIC-FO (hepatic arterial infusion chemotherapy),sorafenib,overall survival,"open-label, phase III trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
41,patients with hepatocellular carcinoma and microvascular invasion,sintilimab (PD-1 inhibitor),active surveillance,"recurrence-free survival, overall survival","multicenter, open-label, randomized, controlled, phase 2 trial",False,Study design is not CheckMate RCT
42,patients with unresectable hepatocellular carcinoma,atezolizumab + bevacizumab,sorafenib,"objective response rate, duration of response",phase III trial,False,Study design is not CheckMate RCT
43,patients with hepatocellular carcinoma,POSTN gene knockdown,not specified,"tumor growth, stemness factors",not specified,False,"Intervention is not ICIs, and study design is not RCT"
44,patients with hepatocellular carcinoma and macroscopic vascular invasion,TACE plus external beam radiotherapy,sorafenib,"progression-free survival, overall survival","randomized, open-label clinical trial",False,Intervention is not ICIs
45,patients with advanced hepatocellular carcinoma,atezolizumab + bevacizumab,sorafenib,"patient-reported outcomes, quality of life","open-label, randomized, phase 3 trial",False,Study design is not CheckMate RCT
46,patients with advanced hepatocellular carcinoma,selective internal radiotherapy (SIRT),sorafenib,overall survival,"multicenter, open-label, randomized, controlled, phase 3 trial",False,Intervention is not ICIs
47,patients with hepatocellular carcinoma,sorafenib,placebo,recurrence-free survival,phase 3 trial,False,"Intervention is not ICIs, and study design is not CheckMate RCT"
48,patients with recurrent intermediate-stage hepatocellular carcinoma,sorafenib plus TACE,TACE alone,"overall survival, progression-free survival","phase 3, open-label, multicenter randomized clinical trial",False,Intervention is not ICIs
49,patients with previously untreated advanced hepatocellular carcinoma,cabozantinib plus atezolizumab,sorafenib,"overall survival, progression-free survival","open-label, randomized, phase 3 study",False,Study design is not CheckMate RCT
50,patients with advanced hepatocellular carcinoma,nivolumab plus ipilimumab,different dosing regimens of nivolumab and ipilimumab,"objective response rate, duration of response, overall survival",randomized controlled trial (CheckMate 040),True,"matches PICOS criteria: population, intervention, comparison, outcome, and study design"
51,patients with hepatocellular carcinoma,proton beam radiotherapy,transarterial chemoembolization,"overall survival, progression-free survival, local control",randomized controlled trial,False,intervention and comparison do not match PICOS criteria (not ICIs)
52,HBV-related HCC patients with intermediate or high risk of recurrence,adjuvant transarterial chemoembolization,no adjuvant treatment,"recurrence-free survival, overall survival",randomized phase 3 trial,False,intervention and comparison do not match PICOS criteria (not ICIs)
53,patients with unresectable hepatocellular carcinoma,STRIDE regimen (tremelimumab plus durvalumab),sorafenib,"patient-reported outcomes (quality of life, functioning, symptoms)",randomized phase 3 trial (HIMALAYA),False,outcome does not match PICOS criteria (not survival or response rate)
54,patients with unresectable hepatocellular carcinoma,tremelimumab plus durvalumab,sorafenib,overall survival,randomized phase 3 trial (HIMALAYA),True,"matches PICOS criteria: population, intervention, comparison, outcome, and study design"
55,patients with hepatocellular carcinoma with portal vein tumor thrombus,sorafenib plus transarterial chemoembolization,sorafenib alone,"recurrence-free survival, overall survival",randomized phase 3 trial,False,intervention and comparison do not match PICOS criteria (not ICIs)
56,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,health-related quality of life,randomized phase 3 trial (REFLECT),False,outcome does not match PICOS criteria (not survival or response rate)
57,patients with hepatocellular carcinoma,radiation therapy,not specified,"local control, survival",not specified,False,intervention and study design do not match PICOS criteria (not ICIs or RCT)
58,patients with hepatocellular carcinoma,TACE-DEB,stereotactic body radiation therapy,"time to progression, local control, overall survival",randomized trial,False,intervention and comparison do not match PICOS criteria (not ICIs)
59,patients with advanced hepatocellular carcinoma,nivolumab plus cabozantinib with or without ipilimumab,not specified,"objective response rate, progression-free survival, overall survival",phase I/II trial (CheckMate 040),True,"matches PICOS criteria: population, intervention, outcome, and study design (CheckMate RCT)"
60,patients with hepatocellular carcinoma and Vp4 PVTT,irradiation stent placement plus TACE,sorafenib plus TACE,"overall survival, hepatic function, time to symptomatic progression, disease control rate",multicenter randomized controlled trial,False,intervention is not immune checkpoint inhibitors
61,massive hepatocellular carcinoma patients,camrelizumab plus TACE,TACE alone,"clinical efficacy, adverse events, liver function, biomarker levels",prospective randomized trial,False,study design is not CheckMate RCT
62,unresectable hepatocellular carcinoma patients,Tislelizumab,Sorafenib,"cost-effectiveness, quality-adjusted life-years",partitioned survival model,False,study design is not CheckMate RCT
63,nonresected hepatocellular carcinoma patients,lenvatinib,sorafenib,"cost-effectiveness, quality-adjusted life-years",Markov model,False,study design is not CheckMate RCT
64,intermediate stage hepatocellular carcinoma patients,TACE plus sorafenib,TACE alone,"time-to-complete response, time-to-TACE progression, progression-free survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
65,advanced hepatocellular carcinoma patients,TACE followed by HAIC with or without S-1,TACE followed by HAIC,"progression-free survival, overall survival, objective response rate",single-center randomized controlled trial,False,intervention is not immune checkpoint inhibitors
66,hepatocellular carcinoma patients undergoing TACE,prophylactic antibiotics,different antibiotic groups,"infection prevention, safety",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
67,hepatocellular carcinoma patients exceeding Milan criteria,neoadjuvant pembrolizumab plus lenvatinib,control group without neoadjuvant therapy,"recurrence-free survival, tumor necrosis",prospective randomized pilot study,False,study design is not CheckMate RCT
68,hepatocellular carcinoma patients,nomogram based on HCC-GRIm score,not specified,"prognosis prediction, survival time",retrospective cohort study,False,study design is not CheckMate RCT
69,inoperable stage III hepatocellular carcinoma patients,sunitinib plus TACE,sorafenib plus TACE,"overall survival, progression-free survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
70,patients with intermediate stage multinodular HCC,DEB-TACE plus sorafenib,placebo plus DEB-TACE,"time-to-tumor progression, overall survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
72,patients with advanced HCC previously treated with sorafenib,pembrolizumab,placebo,"life-years, quality-adjusted life-years, overall survival",randomized placebo-controlled trial,True,matches all PICOS criteria
73,patients with HCC not suitable for surgical resection,sunitinib plus doxorubicin-TACE,placebo plus doxorubicin-TACE,"progression-free survival, overall survival, bleeding or liver failure","randomized, double-blind study",False,intervention is not immune checkpoint inhibitors
74,HCC patients with portal vein tumor thrombus,DEB-TACE,conventional TACE,"progression-free survival, overall survival, adverse events",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
75,patients with asymptomatic synchronous unresectable CRLMs,pre-PTR chemotherapy,upfront PTR,"progression-free survival, overall survival, disease control rate",randomized controlled trial,False,population is not hepatocellular carcinoma
76,HCC patients who underwent hepatectomy,postoperative adjuvant transarterial chemoembolization,no PA-TACE,"disease-free survival, overall survival",retrospective analysis,False,intervention is not immune checkpoint inhibitors
77,HCC patients after narrow-margin hepatectomy,radiotherapy,transarterial chemoembolization,"overall survival, progression-free survival, recurrence patterns",prospective randomized study,False,intervention is not immune checkpoint inhibitors
78,HCC patients with high recurrence risk,PD-1 inhibitors,no PD-1 inhibitors,"relapse-free survival, overall survival, recurrence modality",single-arm phase 2 trial,True,matches all PICOS criteria
79,HR+/Her2- locally advanced breast cancer patients,DEB-TACE combined with systemic chemotherapy,systemic chemotherapy alone,"overall response rate, pathological complete response, adverse reactions",controlled study,False,population is not hepatocellular carcinoma
71,not applicable,not applicable,not applicable,not applicable,not applicable,False,Abstract too short or empty
80,patients with locally advanced HCC,yttrium-90 resin microspheres RE,sorafenib,overall survival,"open-label, phase III trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
81,patients with HCC and PVTT,TACE plus lenvatinib,TACE plus sorafenib,"time-to-progression, objective response rate","open-label, single-center, randomized trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
82,patients with Child-Pugh class B/C HCC,sorafenib,best supportive care,"progression-free survival, overall survival",three-center open-label study,False,Intervention is not immune checkpoint inhibitors (ICIs)
83,patients with unresectable HCC,TACE with dicycloplatin,TACE with epirubicin,"objective response rate, disease control rate","randomized, open-label, phase II trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
84,"patients with advanced solid tumors, including HCC",SAR'459 ± cemiplimab,not specified,"antitumor activity, safety",phase I/Ib study,False,Intervention is not immune checkpoint inhibitors (ICIs)
85,patients with HBV-related HCC and PHT,partial hepatectomy,interventional treatment (ablation ± TACE),"overall survival, recurrence-free survival",open-label randomized clinical trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
86,patients with advanced HCC and ALBI grade 1/2,cabozantinib,placebo,"overall survival, progression-free survival",phase 3 CELESTIAL trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
87,patients with renal cell carcinoma,DEE transarterial chemoembolization,transarterial embolization,"necrosis, safety",randomized trial,False,Population is not hepatocellular carcinoma (HCC)
88,patients with unresectable HCC,lenvatinib,sorafenib,"overall survival, progression-free survival","open-label, noninferiority trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
89,patients with HCC undergoing TACE,TACE via transradial or transfemoral access,not specified,radiation dose received by operator,randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
90,patients with advanced hepatocellular carcinoma,doxorubicin plus sorafenib,sorafenib alone,overall survival and progression-free survival,randomized phase III trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
91,patients with advanced hepatocellular carcinoma,sorafenib combined with cTACE,sorafenib alone,"overall survival, time to progression, progression-free survival, tumor response rate",randomized phase III trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
92,patients with advanced hepatocellular carcinoma,SIRT plus sorafenib,sorafenib alone,overall survival,subanalysis of a randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
93,patients with hepatocellular carcinoma and portal vein tumor thrombus,radiotherapy prior to TACE,TACE followed by radiotherapy,"overall survival, progression-free survival",randomized controlled study,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
94,patients with hepatocellular carcinoma,sorafenib or SIRT plus sorafenib,not specified,overall survival,subanalysis of a randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
95,patients with unresectable hepatocellular carcinoma,DEB-TACE combined with apatinib,DEB-TACE monotherapy,"progression-free survival, overall survival, response rates",randomized phase III trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
96,patients with unresectable hepatocellular carcinoma,DEB-TACE with CalliSpheres microspheres,conventional TACE,"overall survival, progression-free survival, response rates",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
97,patients with advanced hepatocellular carcinoma,SIRT plus sorafenib,sorafenib alone,overall survival,randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
98,patients with unresectable hepatocellular carcinoma,raltitrexed plus OXA-based TACE,fluorouracil or doxorubicin plus OXA-based TACE,"overall survival, progression-free survival, response rates",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors (ICIs)
99,patients with unresectable hepatocellular carcinoma,camrelizumab plus rivoceranib,sorafenib,"overall survival, progression-free survival",randomized phase III trial,True,Intervention involves immune checkpoint inhibitors (camrelizumab) and matches all PICOS criteria
100,patients with hepatocellular carcinoma,DEB-TACE,not specified,ALFD prediction,retrospective study,False,Intervention and outcome do not match PICOS criteria.
101,patients with advanced hepatocellular carcinoma,sorafenib and SIRT,not specified,overall survival and liver decompensation,post hoc analysis,False,Intervention and study design do not match PICOS criteria.
102,patients with advanced hepatocellular carcinoma,cabozantinib,placebo,overall survival and progression-free survival,randomized controlled trial,False,Intervention does not match ICIs in PICOS criteria.
103,patients with HBV-related unresectable hepatocellular carcinoma,lenvatinib,sorafenib,overall survival and progression-free survival,retrospective study,False,Intervention and study design do not match PICOS criteria.
104,patients with unresectable hepatocellular carcinoma,sorafenib,placebo,overall survival,pooled exploratory analysis,False,Intervention does not match ICIs in PICOS criteria.
105,patients with unresectable hepatocellular carcinoma,lenvatinib,sorafenib,overall survival,biomarker analysis,False,Intervention and study design do not match PICOS criteria.
106,patients with hepatocellular carcinoma,sorafenib,placebo,RFA efficacy,randomized controlled trial,False,Intervention and outcome do not match PICOS criteria.
107,patients with unresectable hepatocellular carcinoma,HAIC,not specified,therapeutic response,retrospective study,False,Intervention and outcome do not match PICOS criteria.
108,patients with unresectable hepatocellular carcinoma,TACE with miriplatin,TACE with epirubicin,overall survival,randomized controlled trial,False,Intervention does not match ICIs in PICOS criteria.
109,patients with advanced hepatocellular carcinoma,SIRT + sorafenib,sorafenib alone,treatment response prediction,randomized controlled trial,False,Intervention and outcome do not match PICOS criteria.
110,patients with hepatocellular carcinoma,Stereotactic Body Radiotherapy (SBRT),standard TAE/TACE,"1-year local control, progression-free survival, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
111,patients with hepatocellular carcinoma,Cidan Capsule combined with TACE,TACE alone,"disease-free survival, tumor recurrence rate, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
112,patients with advanced hepatocellular carcinoma,SIRT + sorafenib,sorafenib alone,"survival benefit, liver function",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
113,patients with advanced hepatocellular carcinoma,sorafenib + pravastatin,sorafenib alone,"overall survival, progression-free survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
114,patients with advanced hepatocellular carcinoma,ramucirumab,placebo,"overall survival, post-progression survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
115,patients with hepatocellular carcinoma,repeated cTACE,not specified,overall survival,retrospective study,False,Intervention is not immune checkpoint inhibitors (ICIs)
116,patients with hepatocellular carcinoma,sorafenib + vitamin K2,sorafenib alone,"progression-free survival, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
117,patients with medium-advanced hepatocellular carcinoma,TACE with bleomycin,TACE without bleomycin,"overall survival, progression-free survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
118,patients with hepatocellular carcinoma,TACE with low-dose doxorubicin,TACE with high-dose doxorubicin,"overall survival, post-embolisation syndrome",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
119,patients with advanced hepatocellular carcinoma,TIPS,endoscopic + β-blocker therapy,"rebleeding, overall survival",randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
120,patients with unresectable and advanced HCC,TACE combined with celecoxib and lanreotide,TACE alone,"overall survival, disease control rate",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
121,patients with HCC admitted for TACE,intravenous NAC,placebo,incidence of post-embolization syndrome,randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
122,patients with primary liver cancer,FJXF combined with TACE,TACE alone,"disease control rate, liver biochemistry",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
123,patients with HCC >3-<5 cm,combined therapy with cTACE and MWA,TACE or MWA alone,"complete response, recurrence rate, overall survival",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
124,patients with unresectable HCC,TACE with cisplatin,TACE with epirubicin,"overall survival, tumor response",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
125,patients with unresectable HCC,SIRT using yttrium resin microspheres,sorafenib,overall survival,post-hoc analysis of SARAH trial,False,Intervention does not involve immune checkpoint inhibitors
126,patients with gastroesophageal junction cancer and hepatic metastasis,transarterial infusion chemotherapy plus microsphere embolization,transarterial infusion chemotherapy alone,"median survival time, survival rates",randomized controlled trial,False,Population does not match hepatocellular carcinoma
127,patients with primary hepatic carcinoma,lobaplatin in TACE,pirarubicin hydrochloride in TACE,"survival time, therapeutic response",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
128,HCC patients resistant to TACE with doxorubicin,TACE with bleomycin,TACE with doxorubicin,"progression-free survival, overall survival",randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
129,"patients with unresectable, liver-confined HCC",TACE with sorafenib,TACE with placebo,progression-free survival,randomized controlled trial,False,Intervention does not involve immune checkpoint inhibitors
130,patients with CRLM,TACE with DSM or lipiodol,TACE with lipiodol vs DSM,tumor response and survival rate,"prospective, randomized, single-center trial",False,"Population is CRLM, not hepatocellular carcinoma; intervention is not ICIs."
131,patients with HCC,prophylactic HAIC,HAIC vs no HAIC,"intrahepatic recurrence-free survival, disease-free survival, overall survival",randomized trial,False,"Intervention is HAIC, not ICIs; no comparison to placebo or non-ICI treatment."
132,patients with HCC and tumor portal invasion,percutaneous ablation,ablation vs sorafenib or TARE,"overall survival, progression-free survival",retrospective study with propensity-score matching,False,"Intervention is ablation, not ICIs; study design is not CheckMate RCT."
133,patients with HCC,TRA vs TFA for TACE,TRA vs TFA,"patient satisfaction, procedural variables, safety",randomized trial,False,"Intervention is TRA/TFA, not ICIs; outcomes are not survival or response rate."
134,patients with HCC and PVTT,"LR, TACE, or sorafenib",LR vs TACE vs sorafenib,overall survival,randomized trial,False,"Interventions are LR, TACE, or sorafenib, not ICIs; study design is not CheckMate RCT."
135,HBV-related HCC patients,TACE with lamivudine,TACE with lamivudine vs TACE alone,"time to progression, overall survival",randomized trial,False,"Intervention is TACE with lamivudine, not ICIs; study design is not CheckMate RCT."
136,patients with aHCC,sorafenib-GEMOX vs sorafenib,sorafenib-GEMOX vs sorafenib alone,"progression-free survival, overall survival",multicentre phase II trial,False,"Intervention is sorafenib-GEMOX, not ICIs; study design is not CheckMate RCT."
137,patients with unresectable HCC,TEA vs TACE,TEA vs TACE,"overall survival, time to progression, progression-free survival",randomized controlled trial,False,"Interventions are TEA and TACE, not ICIs; study design is not CheckMate RCT."
138,patients with HCC and AFP ≥400 ng/mL,ramucirumab,ramucirumab vs placebo,"overall survival, progression-free survival, time to progression",post-hoc analysis of REACH and REACH-2 trials,False,"Intervention is ramucirumab, not ICIs; study design is not CheckMate RCT."
139,HBV-related HCC patients,TACE,not specified,severe abdominal pain post-TACE,randomized trial,False,"Intervention is TACE, not ICIs; outcomes are not survival or response rate."
140,patients with advanced HCC,sorafenib plus hepatic arterial infusion chemotherapy with cisplatin,sorafenib alone,"overall survival, time to progression, response rate",multicenter open-labeled randomized phase II trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
141,patients with stage B or C liver cancer,early percutaneous transhepatic varices embolization (PTVE),no PTVE,"hemorrhage rates, recurrence rates, liver function, tumor control",retrospective study,False,Intervention is not ICIs; study design is not RCT
142,patients with medium-sized HCC,sorafenib combined with radiofrequency ablation (RFA),RFA alone,"recurrence rates, time to progression, adverse reactions",randomized trial,False,Intervention is not ICIs
143,patients with advanced HCC,linifanib,sorafenib,"overall survival, time to progression, objective response rate",open-label phase III trial,False,Intervention is not ICIs
144,patients with locally advanced or inoperable HCC,transarterial radioembolisation (TARE),sorafenib,health-related quality of life,randomized trial,False,Intervention is not ICIs
145,patients with HCC,not specified,not specified,quality of life impact of adverse events,analysis of SARAH RCT data,False,Intervention is not ICIs
146,patients with unresectable HCC undergoing TACE,"celecoxib, parecoxib, oxycodone",not specified,"pain control, adverse events","randomized, paralleled trial",False,Intervention is not ICIs
147,patients with sorafenib-refractory advanced HCC,S-1,placebo,"overall survival, adverse events","randomized, double-blind, placebo-controlled phase III study",False,Intervention is not ICIs
148,patients with advanced HCC,sorafenib plus metformin,sorafenib alone,"treatment response, time to progression, overall survival","prospective, randomized study",False,Intervention is not ICIs
149,patients with HCC receiving sorafenib,sorafenib monotherapy,not specified,"overall survival, objective response",prospective multicenter phase II trial,False,Intervention is not ICIs
150,patients with unresectable HCC,DEM-TACE,c-TACE,12- and 24-month survival rates,randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
151,patients with primary hepatic carcinoma,TACE plus Huaier granule,TACE alone,overall survival and tumor response rates,randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
152,patients with HCC requiring TACE,TACE plus LMWH,TACE alone,incidence of PVT,randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
153,patients with liver cancer after TACE,individualized nutritional intervention,routine dietary intervention,nutritional status and liver function,randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
154,patients with resectable multiple HCC,partial hepatectomy,TACE,overall survival,randomized comparative trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
155,patients with unresectable HCC,SIRT,TACE,safety and health-related quality of life,randomized-controlled pilot study,False,Intervention is not immune checkpoint inhibitors (ICIs)
156,patients with large or huge HCC,CBATO-TACE,cTACE,progression-free survival and overall survival,randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
157,patients with unresectable HCC,image-guided HDR brachytherapy,cTACE,time to untreatable progression and overall survival,randomized phase II study,False,Intervention is not immune checkpoint inhibitors (ICIs)
158,patients with advanced HCC,regorafenib,placebo,cost-effectiveness and survival,randomized controlled trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
159,patients with unresectable HCC,atezolizumab and bevacizumab,sorafenib,cost-effectiveness and quality-adjusted life years,phase III randomized trial,False,Intervention includes ICIs but comparison is not treatment without ICIs or placebo
160,patients with Hepatocellular Carcinoma with Child-Pugh B cirrhosis,"sorafenib, pravastatin, or combination",best supportive care,"time to progression, overall survival",multicentric prospective non-comparative randomized trial,False,Intervention does not match ICIs; study design is not CheckMate RCT
161,patients with advanced hepatocellular carcinoma,urea-based cream,best supportive care,incidence of hand-foot skin reaction,randomised double-blind experimental study,False,Intervention does not match ICIs; outcome does not match survival or response rate
162,patients with advanced hepatocellular carcinoma,trebananib plus sorafenib,historical control (sorafenib),"progression-free survival, overall survival",nonrandomized cohorts,False,Intervention does not match ICIs; study design is not CheckMate RCT
163,patients with hepatocellular carcinoma,gadobenate dimeglumine-enhanced MR,not specified,tumor response after TACE,not specified,False,Intervention does not match ICIs; outcome does not match survival or response rate
164,patients with unresectable hepatocellular carcinoma,DEB-TACE with doxorubicin-loaded CalliSpheres,cTACE with doxorubicin-lipiodol emulsion,"clinical response rate, overall survival, progression-free survival",randomized controlled trial,False,Intervention does not match ICIs; study design is not CheckMate RCT
165,cirrhotic hepatocellular carcinoma patients,L-carnitine,control group,liver function after TACE,not specified,False,Intervention does not match ICIs; outcome does not match survival or response rate
166,patients with hepatocellular carcinoma,cabozantinib,placebo,"overall survival, progression-free survival",Phase III CELESTIAL trial,False,Intervention does not match ICIs; study design is not CheckMate RCT
167,patients with unresectable hepatocellular carcinoma,HAIC combined with donafenib,HAIC alone,"progression-free survival, tumor markers",randomized controlled trial,False,Intervention does not match ICIs; study design is not CheckMate RCT
168,patients undergoing DEE-TACE for hepatocellular carcinoma,hepatic hilar and celiac plexus nerve blocks,standard intraprocedural local anesthetic,"pain, patient satisfaction, adverse events","prospective, randomized trial",False,Intervention does not match ICIs; outcome does not match survival or response rate
169,unresectable BCLC stage B HCC Child Pugh A patients,TACE followed by SBRT,TACE alone,"local control, progression-free survival, overall survival",randomized controlled trial,False,Intervention does not match ICIs; study design is not CheckMate RCT
170,patients with hepatocellular carcinoma,transarterial radioembolization (TARE),sorafenib,"survival rate, quality-adjusted life-years (QALYs)",randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
171,patients with HCC awaiting liver transplantation,sorafenib plus radioembolization (Y90),Y90 alone,"survival rates, adverse events",randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
172,patients with primary liver cancer,TACE plus high intensity focused ultrasound (HIFU),TACE alone,"remission rate, tumor recurrence, metastasis rate",randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
173,patients with hepatocellular carcinoma undergoing TACE,preoperative interview and prospective nursing,routine nursing care,"pain, satisfaction, complications",randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
174,patients with advanced hepatocellular carcinoma,regorafenib,placebo,"overall survival, progression-free survival","randomized, placebo-controlled trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
175,patients with hepatocellular carcinoma,embolization with microspheres alone or doxorubicin-eluting microspheres,embolization with microspheres alone,"response rate, progression-free survival, overall survival",randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
176,patients with TACE-eligible hepatocellular carcinoma,brivanib,placebo,"overall survival, time to disease progression","randomized, double-blind, placebo-controlled trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
177,patients with hepatocellular carcinoma undergoing TACE,not specified,not specified,liver abscess formation,retrospective review,False,Intervention is not immune checkpoint inhibitors (ICIs)
178,patients with advanced hepatocellular carcinoma,enzalutamide,placebo,"overall survival, progression-free survival","randomized, double-blind, placebo-controlled trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
179,patients with inoperable intermediate- or advanced-stage hepatocellular carcinoma,radioembolization with yttrium-90 followed by sorafenib,sorafenib only,"safety, adverse events",randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
180,patients with advanced hepatocellular carcinoma,donafenib,not specified,"safety, pharmacokinetics, and efficacy",phase 1b trial,False,"intervention is not immune checkpoint inhibitors, no comparison to placebo or non-ICI treatment"
181,patients with liver cancers,transcutaneous electrical acustimulation (TEA),sham-TEA,"GI symptoms, gastric slow waves, autonomic functions",randomized trial,False,"population not specific to hepatocellular carcinoma, intervention not ICIs"
182,patients with advanced hepatocellular carcinoma and AFP ≥400 ng/mL,ramucirumab,placebo,"overall survival, progression-free survival",randomized phase 3 trial,False,intervention is not immune checkpoint inhibitors
183,second-line hepatocellular carcinoma patients,tivantinib,placebo,"survival, biomarker analysis",randomized phase II trial,False,intervention is not immune checkpoint inhibitors
184,pediatric hepatoblastoma patients,HIFU combined with TACE,TACE alone,"survival, immune function, side effects",comparative study,False,"population is pediatric hepatoblastoma, not hepatocellular carcinoma"
185,intermediate-stage hepatocellular carcinoma patients,LIPDOX or DEBDOX,not specified,"pharmacokinetics, safety, antitumor effects","open, prospective, nonrandomized multicenter study",False,"intervention is not immune checkpoint inhibitors, no comparison to placebo or non-ICI treatment"
186,intermediate-stage hepatocellular carcinoma patients,dexamethasone,placebo,"postembolization syndrome, hospitalization time","randomized, double-blinded, placebo-controlled trial",False,intervention is not immune checkpoint inhibitors
187,patients with hepatocellular carcinoma,cabozantinib,placebo,"objective response rate, progression-free survival",phase 2 randomized discontinuation trial,False,intervention is not immune checkpoint inhibitors
188,Taiwanese patients with advanced hepatocellular carcinoma,sorafenib,not specified,"overall survival, progression-free survival, safety",phase IV study,False,intervention is not immune checkpoint inhibitors
189,patients with intermediate and advanced hepatocellular carcinoma,TACE combined with apatinib,TACE alone,"progression-free survival, adverse reactions",randomized trial,False,intervention is not immune checkpoint inhibitors
190,patients with primary carcinoma of the liver,TACE with lobaplatin,TACE with cisplatin,efficacy and adverse events,randomized controlled trial,False,intervention is not immune checkpoint inhibitors
191,patients with advanced HCC,sorafenib,not specified,"overall survival, time to progression, response rate",retrospective analysis,False,intervention is not immune checkpoint inhibitors
192,patients with HCC beyond Milan criteria,surgical resection or TACE,not specified,survival prediction,nomogram development,False,intervention is not immune checkpoint inhibitors
193,patients with advanced HCC and AFP ≥400 ng/mL,ramucirumab,placebo,time to deterioration in symptoms and quality of life,phase 3 RCT,False,intervention is not immune checkpoint inhibitors
194,patients with advanced HCC,sorafenib,not specified,overall survival and toxicity,multicenter phase II study,False,intervention is not immune checkpoint inhibitors
195,patients with advanced HCC,sorafenib with or without erlotinib,placebo,overall survival and time to progression,phase III RCT,False,intervention is not immune checkpoint inhibitors
196,patients with advanced HCC,dovitinib,sorafenib,overall survival and time to progression,randomized phase 2 study,False,intervention is not immune checkpoint inhibitors
197,patients with HCC on waiting list for liver transplantation,TACE plus sorafenib,TACE plus placebo,"time to progression, tumor response, progression-free survival",randomized double-blind trial,False,intervention is not immune checkpoint inhibitors
198,patients with unresectable HCC,miriplatin/DDP-H combination therapy,miriplatin monotherapy,progression-free survival and disease control rate,randomized phase II study,False,intervention is not immune checkpoint inhibitors
199,patients with primary hepatocellular carcinoma,TACE,radiofrequency ablation,"short-term curative effect, serum biomarkers, liver function",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
200,patients with advanced HCC,CF-HAIC vs ACF-HAIC,CF-HAIC vs ACF-HAIC,"overall survival, treatment response","randomized, open-labeled clinical trial",False,"intervention not ICIs, comparison not placebo or no ICIs"
201,advanced HCC patients who failed prior systemic therapy,codrituzumab,placebo,"progression-free survival, overall survival",randomized phase II trial,False,"intervention not ICIs, study design not CheckMate RCT"
202,advanced HCC with pulmonary metastasis,arsenic trioxide intravenous infusion,TACE alone,"overall survival, clinical efficacy",randomized trial,False,"intervention not ICIs, study design not CheckMate RCT"
203,HCC patients who failed sorafenib,doxorubicin-loaded nanoparticles,standard care,overall survival,randomized phase 3 trial,False,"intervention not ICIs, study design not CheckMate RCT"
204,patients with HCC,DP-CBCT-based navigation imaging during TACE,conventional DSA,"tumor detectability, embolization success",randomized study,False,"intervention not ICIs, study design not CheckMate RCT"
205,HCC patients on sorafenib,urea cream,placebo cream,"HFSR incidence, quality of life",randomized trial,False,"intervention not ICIs, study design not CheckMate RCT"
206,HCC patients,TACE with different anticancer agents,single-drug vs double-drug vs triple-drug TACE,"overall survival, time to progression",randomized trial,False,"intervention not ICIs, study design not CheckMate RCT"
207,early-intermediate stage HCC patients,TACE combined with sorafenib,TACE alone,overall survival,post hoc analysis of START trial,False,"intervention not ICIs, study design not CheckMate RCT"
208,unresectable HCC with lung metastasis,arsenic trioxide TACE and intravenous administration,arsenic trioxide TACE alone,"overall survival, time to progression",randomized trial,False,"intervention not ICIs, study design not CheckMate RCT"
209,cirrhotic HCC patients with PVTT,RFA of HCC and PVTT plus sorafenib,sorafenib alone,3-year survival,randomized controlled trial,False,"intervention not ICIs, study design not CheckMate RCT"
210,patients with advanced hepatocellular carcinoma,bevacizumab and erlotinib,sorafenib,"overall survival, event-free survival, response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
211,HCC patients with solitary tumor and microvascular invasion,adjuvant TACE after hepatectomy,hepatectomy alone,"disease-free survival, overall survival",randomized phase III trial,False,intervention is not immune checkpoint inhibitors
212,HCC patients undergoing TACE,dexamethasone regimen,placebo regimen,complete response rate for adverse events,"randomized, double-blind, placebo-controlled trial",False,intervention is not immune checkpoint inhibitors
213,patients with hepatic cell carcinoma,TACE combined with RFA,TACE alone,"overall effect, serum markers",randomized trial,False,intervention is not immune checkpoint inhibitors
214,patients with advanced HCC,resminostat plus sorafenib,sorafenib monotherapy,"time-to-progression, overall survival",phase I/II study,False,intervention is not immune checkpoint inhibitors
215,Child-Pugh A patients with advanced HCC,sorafenib plus mFOLFOX,not specified,"time-to-progression, overall survival",single-arm phase II study,False,intervention is not immune checkpoint inhibitors
216,"patients with advanced, unresectable HCC",sorafenib plus hepatic arterial infusion chemotherapy,sorafenib alone,overall survival,randomized phase III trial,False,intervention is not immune checkpoint inhibitors
217,patients with advanced HCC and PVTT,HAIC,sorafenib,"overall survival, time to progression","randomized, prospective, comparative study",False,intervention is not immune checkpoint inhibitors
218,patients with advanced HCC,sequential HAIC with cisplatin followed by sorafenib,sorafenib alone,"one-year survival rate, overall survival",randomized phase II study,False,intervention is not immune checkpoint inhibitors
219,patients with HCC within Milan criteria,TACE plus RFA,partial hepatectomy,"overall survival, recurrence-free survival",randomized clinical trial,False,intervention is not immune checkpoint inhibitors
220,patients with unresectable HCC and incomplete response after initial TACE,stereotactic ablative radiotherapy (SABR),re-TACE,"1-year freedom-from-local-progression rate, overall survival, response rate","open-label, parallel, randomized controlled trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
221,patients with nonresectable single-lesion HCC,radiofrequency or microwave ablation combined with transcatheter arterial chemoembolization,transcatheter arterial chemoembolization alone,"success rate, complications, tumor response",not specified,False,Intervention is not immune checkpoint inhibitors (ICIs)
222,patients with inoperable HCC,transarterial chemoembolization with stable or unstable emulsions,stable vs unstable emulsions,"overall survival, time to progression, tumor response","single-center, prospective double-blind trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
223,patients with unresectable or metastatic HCC and Child-Pugh ≤7,sorafenib alone or combined with everolimus,sorafenib alone vs sorafenib + everolimus,"progression-free survival, overall survival, response rate",randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
224,patients with advanced HCC and Child-Pugh A liver function,everolimus,placebo,"overall survival, time to progression, disease control rate","randomized, double-blind, phase 3 study",False,Intervention is not immune checkpoint inhibitors (ICIs)
225,patients with HCC receiving preoperative TACE,TACE,not specified,"recurrence rate, disease-free survival",retrospective study,False,Intervention is not immune checkpoint inhibitors (ICIs)
226,patients with HCC who progressed on sorafenib with AFP ≥400 ng/ml,ramucirumab,placebo,"quality-adjusted life years, cost-effectiveness",Markov model analysis,False,Intervention is not immune checkpoint inhibitors (ICIs)
227,patients with advanced HCC (BCLC stage C),TACE combined with ginsenoside Rg3,TACE alone,"overall survival, time to progression, disease control rate","single-center, open-label, randomized controlled trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
228,patients with advanced HCC,AEG35156 combined with sorafenib,sorafenib alone,"progression-free survival, overall survival, objective response rates","multicenter, randomized, open-label, phase II trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
229,patients with locally advanced HCC (BCLC stage B or C),Selective Internal Radiation Therapy (SIRT),sorafenib,"overall survival, tumor response rate, progression-free survival","multi-centre, open-label, randomized, controlled trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
230,patients with intrahepatic cholangiocellular carcinoma,chemoembolization or radioembolization,chemoembolization vs. radioembolization,"progression-free survival, overall survival, time to progression","randomized, controlled, single center, phase II trial",False,"Population is cholangiocellular carcinoma, not hepatocellular carcinoma"
231,patients with newly diagnosed hepatocellular carcinoma,transarterial chemoembolization (TACE),TACE vs. proton beam radiation therapy,"progression-free survival, overall survival, local tumor control","prospective, randomized clinical trial",False,Intervention is not immune checkpoint inhibitors
232,advanced hepatocellular carcinoma patients with prior sorafenib,ramucirumab,ramucirumab vs. placebo,"quality of life, performance status",phase III placebo-controlled randomised study,False,Intervention is not immune checkpoint inhibitors
233,patients with primary or secondary liver cancer,transarterial chemoembolization (TACE),old vs. new C-arm imaging platform,"radiation exposure, image quality","prospective, two-arm trial",False,Population and intervention do not match PICOS criteria
234,patients with advanced hepatocellular carcinoma,sorafenib and bevacizumab,sorafenib and bevacizumab vs. sorafenib alone,"time to progression, survival",phase I/II trial,False,Intervention is not immune checkpoint inhibitors
235,patients with hepatocellular carcinoma,doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) and sorafenib,not specified,"volumetric functional MRI metrics, survival",single center study,False,Intervention is not immune checkpoint inhibitors
236,patients with advanced hepatocellular carcinoma,mapatumumab and sorafenib,mapatumumab and sorafenib vs. placebo and sorafenib,"time to progression, progression-free survival, overall survival","randomized, double-blind, placebo-controlled, phase II study",False,Intervention is not immune checkpoint inhibitors
237,patients with hepatocellular carcinoma,Jian Pi Li Qi (JPLQ) decoction,JPLQ vs. placebo vs. no treatment,"quality of life, liver function","randomized, double-blind, placebo-controlled trial",False,Intervention is not immune checkpoint inhibitors
238,patients with advanced hepatocellular carcinoma,tigatuzumab and sorafenib,tigatuzumab and sorafenib vs. sorafenib alone,"time to progression, overall survival",phase II study,False,Intervention is not immune checkpoint inhibitors
239,patients with inoperable hepatocellular carcinoma,parecoxib sodium,parecoxib sodium vs. placebo,"pain control, quality of life",randomized placebo-controlled prospective clinical study,False,Intervention is not immune checkpoint inhibitors
240,patients with advanced hepatocellular carcinoma,sorafenib plus erlotinib,sorafenib plus placebo,"overall survival, response rate","multicenter, multinational, randomized, phase III trial",False,Intervention is not immune checkpoint inhibitors (ICIs)
241,patients with malignant liver lesions,4D-CTA guided TACE,traditional TACE,"contrast material used, operator radiation exposure, diagnostic confidence",retrospective study,False,Population and intervention do not match PICOS criteria
242,patients with unresectable hepatocellular carcinoma,SIRT,DEB-TACE,"progression-free survival, overall survival",prospective randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
243,HCC patients undergoing repetitive TACE,low-dose X-ray system,reference X-ray system,"patient radiation dose, image quality",randomized study,False,Population and intervention do not match PICOS criteria
244,patients with primary liver cancer after TACE,wrist-ankle acupuncture,oral morphine sulphate,"pain relief, adverse reactions",randomized study,False,Population and intervention do not match PICOS criteria
245,patients with advanced HBV-related HCC,tiopronin supplementation,no tiopronin,"liver function, treatment efficacy",prospective study,False,Intervention is not immune checkpoint inhibitors (ICIs)
246,primary HCC patients,LRT combined with arsenic trioxide,LRT alone,"survival time, therapeutic response",randomized controlled study,False,Intervention is not immune checkpoint inhibitors (ICIs)
247,patients with advanced HCC,nintedanib or sorafenib,not specified,overall survival,Phase II clinical trials,False,Intervention is not immune checkpoint inhibitors (ICIs)
248,patients with MET-high advanced HCC,tivantinib,placebo,overall survival,"phase 3, randomized, double-blind, placebo-controlled study",False,Intervention is not immune checkpoint inhibitors (ICIs)
249,patients with unresectable HCC,lenvatinib,sorafenib,overall survival,Phase 3 REFLECT trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
250,patients with hepatocellular carcinoma,transradial access vs transfemoral access in c-TACE,transradial vs transfemoral access,"technical success, patient comfort, radiation exposure",multicenter prospective study,False,Intervention and outcomes do not match PICOS criteria
251,patients with hepatocellular carcinoma,cTACE with bevacizumab,cTACE with placebo,"radiologic progression, overall survival",randomized controlled double-blind phase II trial,False,Intervention is not immune checkpoint inhibitors
252,patients with unresectable hepatocellular carcinoma,orantinib combined with cTACE,placebo combined with cTACE,overall survival,"randomized, double-blind, placebo-controlled phase 3 study",False,Intervention is not immune checkpoint inhibitors
253,patients with hepatocellular carcinoma,TACE vs SBRT,TACE vs SBRT,radiotherapy quality assurance,international multi-center phase-II study,False,Intervention and outcomes do not match PICOS criteria
254,patients with unresectable advanced hepatocellular carcinoma,nintedanib,sorafenib,"time-to-progression, overall survival",phase-I/randomised phase-II trial,False,Intervention is not immune checkpoint inhibitors
255,patients with hepatocellular carcinoma with PVTT,TACE with iodine-125 seed strand,conventional TACE,survival time,"prospective, randomised, two-arm clinical trial",False,Intervention is not immune checkpoint inhibitors
256,patients with small hepatocellular carcinoma,traditional herbal medicine,TACE,"recurrence-free survival, overall survival",prospective randomized controlled study,False,Intervention is not immune checkpoint inhibitors
257,patients with advanced hepatocellular carcinoma,ramucirumab,placebo,overall survival,"randomised, placebo-controlled, double-blind, phase 3 trial",False,Intervention is not immune checkpoint inhibitors
258,patients with advanced hepatocellular carcinoma,urea-based cream,best supportive care,hand-foot skin reaction,"randomized, open-label trial",False,Intervention and outcomes do not match PICOS criteria
259,patients with advanced hepatocellular carcinoma,radioembolisation with yttrium-90 microspheres,sorafenib,overall survival,"prospective, randomised, controlled, open-label, multicentre trial",False,Intervention is not immune checkpoint inhibitors
260,patients with hepatocellular carcinoma,DEB-TACE,cTACE,"time-to-tumour progression, 2-year survival",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
261,patients with liver cancer,"sorafenib, TACE, sorafenib combined with TACE",TACE or sorafenib alone,"total effective rate, total survival",not specified,False,intervention is not immune checkpoint inhibitors
262,patients with hepatocellular carcinoma previously treated with sorafenib,pembrolizumab plus best supportive care,placebo plus best supportive care,health-related quality of life,randomized controlled trial,False,outcome is not survival or response rate
263,patients with differentiated thyroid carcinoma,sorafenib,not specified,"progression-free survival, adverse events",phase III trial,False,population is not hepatocellular carcinoma
264,patients with radioiodine-refractory differentiated thyroid cancer,lenvatinib,placebo,tumor size change,not specified,False,population is not hepatocellular carcinoma
265,Japanese patients with MET-high hepatocellular carcinoma,tivantinib,placebo,"progression-free survival, overall survival","randomized, double-blind, placebo-controlled trial",False,intervention is not immune checkpoint inhibitors
266,patients with hepatocellular carcinoma progressing during sorafenib treatment,regorafenib,placebo,"overall survival, time to progression",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
267,patients with large hepatocellular carcinoma,TACE with bicarbonate,TACE without bicarbonate,"viable tumor residues, objective response rate",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
268,patients with hepatocellular carcinoma,clinical decision support system,handbook only,"patient-centered caring attitude, pain management",randomized controlled trial,False,intervention is not immune checkpoint inhibitors
269,patients with unresectable hepatocellular carcinoma,radioembolization with sorafenib,radioembolization alone,serum angiogenic markers,randomized pilot study,False,intervention is not immune checkpoint inhibitors
270,patients with advanced hepatocellular carcinoma,brivanib,placebo,overall survival,randomized phase III trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
271,patients with hepatocellular carcinoma and portal vein tumor thrombus,3DCRT followed by TACE,TACE followed by 3DCRT,"efficacy, toxicity, survival rates",randomized study,False,Intervention is not immune checkpoint inhibitors (ICIs)
272,patients receiving lenvatinib,urine protein:creatinine ratio (UPCR),24-hour urine protein,proteinuria monitoring,phase 3 REFLECT study,False,Population and intervention do not match PICOS criteria
273,patients with advanced hepatocellular carcinoma,ADI-PEG 20,placebo,overall survival,randomized study,False,Intervention is not immune checkpoint inhibitors (ICIs)
274,patients with primary or metastatic liver cancer,transcutaneous electrical acupoint stimulation (TEAS),placebo-acupuncture,nausea and vomiting,randomized study,False,Population and intervention do not match PICOS criteria
275,Japanese patients with advanced hepatocellular carcinoma,ramucirumab,placebo,overall survival,randomized study,False,Intervention is not immune checkpoint inhibitors (ICIs)
276,single-nodule small hepatocellular carcinoma patients,preoperative neutrophil-to-lymphocyte ratio (NLR),not specified,"time to recurrence, overall survival",retrospective study,False,Intervention and study design do not match PICOS criteria
277,patients with advanced hepatocellular carcinoma,tivantinib,placebo,survival advantage,randomized phase III study,False,Intervention is not immune checkpoint inhibitors (ICIs)
278,patients with advanced hepatocellular carcinoma,Pexa-Vec (JX-594),not specified,dose-finding,randomized trial,False,Intervention is not immune checkpoint inhibitors (ICIs)
279,advanced hepatocellular carcinoma patients,sorafenib,not specified,"overall survival, progression-free survival",phase III study,False,Intervention is not immune checkpoint inhibitors (ICIs)
280,patients with hepatocellular carcinoma,medical ozone oil,urea ointment,incidence and severity of hand-foot skin reaction,randomized controlled trial,False,intervention is not immune checkpoint inhibitors; outcome is not survival or response rate; study design is not CheckMate RCT
